PTAB Affirms That Overlapping Prior Art Does Not Automatically Lead to Rejection of Follow-­On IPR Petition

Feb 10, 2015

Reading Time : 1 min

On January 28, 2015, the Patent Trial and Appeal Board (PTAB) issued its decision to institute inter partes review in Valeo North America, Inc., et al., v. Magna Electronics, Inc., IPR2014­01203 with Administrative Patent Judges Lee, Kauffman, and Clements presiding. In its decision, the board rejected patent owner’s argument that the petition should be rejected under 35 U.S.C. Section 325(d), which states that the director “may” take into account whether the same or substantially the same prior art arguments previously were presented to the Office in determining whether to institute review. The petitioner had previously filed a petition on the same claims, including some of the same prior art. For example, some claims in the first petition were challenged on the basis of a single reference, and in the follow­on petition, those same claims were challenged on the basis of the same single reference in addition to one or two others. Notably, the board rejected a number of arguments advanced by the patent owner that, (1) the petitioner must affirmatively explain why a follow­on petition is not redundant; and 2) the mere addition of prior art does not preclude rejection under Section 325(d). The board explained that there is no requirement for a petitioner to explain why a follow­on petition is not redundant, and maintained that even though there was overlap in the prior art between petitions, the arguments were not substantially the same in the follow­on petition, and therefore they would not exercise their discretion under Section 325(d).

Valeo North America, Inc., et al., v. Magna Electronics, Inc., IPR2014­01203 (PTAB Jan. 28, 2015) [Lee, Kauffman, and Clements (opinion)].

Share This Insight

Previous Entries

IP Newsflash

June 5, 2026

The Supreme Court unanimously held that for a complaint of induced infringement, a patent owner must allege that the accused infringer took affirmative, not passive, steps to encourage direct infringement. Thus, where a generic drug has a skinny label, to induce infringement of the carved-out patented use of the drug, the generic company must have taken steps that were designed to cause others to perform the patented use, not just steps that could cause such conduct.

...

Read More

IP Newsflash

May 07, 2026

The Northern District of Illinois granted a summary judgment motion of no invalidity based on indefiniteness because the qualitative terms like “sufficiently slow” and “desired period of time” were definite when viewed in light of the surrounding claim language and specification.

...

Read More

IP Newsflash

April 9, 2026

In the April 1, 2026 edition of the Official Gazette, the U.S. Patent and Trademark Office announced a new procedural framework that permits patent owners to submit a limited, early response to a request for ex parte reexamination.

...

Read More

IP Newsflash

March 12, 2026

The Northern District of Illinois recently dismissed a complaint without prejudice for failing to plausibly allege patent infringement. The court found that the allegations of direct infringement were insufficiently pled where the images of the accused product included in the complaint did not appear to show a particular necessary element of the claims.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.